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periods 1.  INTRODUCTION 
The  Committee  for  Veterinary  Medicinal  Products  was 
established  by  Article  16  of  Directive  81/851/EEC  on  the 
approximation  of  laws  of  the  Member  States  relating  to 
veterinary  medicinal  products*  in  order  to  facilitate  the 
adoption  of  common  positions  by  Member  States  with  regard 
to  the  granting  of  marketing  authorizations  by  Member 
States  for  veterinary  medicinal  products.  The  Committee  may 
also  examine  any  question  concerning  the  application  of 
Directive  81/852/EEC  relating  to  analytical,  pharmaco-
toxicological  and  clinical  standards  and  protocols  in 
respect  of  the  testing of  veterinary  medicinal  products. 
In  particular.  the  Committee  is  responsible  for  preparing 
advisory  opinions  on  applications  for  marketing 
authorization  which  are  submitted  using  the  two  special 
Community  procedures,  the  so  called  "Multi-State"  procedure 
established  by  Directive  81/851/EEC  itself,  and  the 
"Concertation  Procedure"  which  was  subsequently  established 
by  Directive  87/22/EEC.  In  addition,  as  the  sole  advisory 
Committee  of  officials  from  Member  States  established at 
Community  level  with  responsibilities  relating  specifically 
to  veterinary  medicines,  the  Committee  also  has  to  advise 
the  Commission  and  Member  States  on  more  general  aspects 
relating  to  veterinary  medicines. 
In  accordance  with  Article  23  of  Directive  81/851/EEC,  the 
Commission  is  required  to  report  periodically  on  the 
activities  of  the  Committee.  A  first  general  report  on  the 
work  of  the  Committee  was  included  in  the  explanatory 
memorandum  of  the  package  of  three  White  Paper  proposals 
for  the  amendment  of  the  veterinary  medicines  directives 
(COM  (88)  779  final),  which  have  now  been  adopted  by  the 
Council.  This  second  report  is  intended  to  provide  a  more 
detailed  account  of  the  activities  of  the  Committee  up  to 
the  end  of  1990.  Further  reports  will  be  produced  at  annual 
intervals. 
*A  complete  list of  the  Community  Directives  relating  to 
veterinary  medicinal  products  is  set  out  in  Annex  I. 
-3-On  15  November  1990,  the  Commission  formally  presented  to 
Council  a  package  of  four  proposals  for  the  future  system 
for  the  free  circulation of  medicinal  proqucts,  for  human 
and  veterinary  use,  within  the  European  Community, 
including  proposals  for  the  establishment  of  a  European 
Medicines  Evaluation  Agency  and  new  centralised  and 
decentralised  Community  authorization  procedures  (COM  (90) 
283  final;  O.J.  N°  C  330,  31.12.1990,  pp  1-32).  It  is  hoped 
that  the  present  report,  which  describes  the  experience  so 
far  acquired  within  the  CVMP,  will  serve  as  the  basis  for 
the  informed  discussion  of  these  proposals  as  they  relate 
to  veterinary  medicinal  products. 
2.  ACTIVITIES  OF  THE  CVMP 
2.1  ~embership of  the  Committee 
In  accordance  with  Article  16  of  Directive  81/851/EEC  and 
the  Rules  of  Procedure  adopted  by  the  Committee 
(III/1267/83  Rev  2),  the  Committee  consists  of  one 
representative  from  each  Member  State  and  one 
representative  from  the  Commission,  appointed  for  a  term 
of  three  years,  renewable.  A  list of  the  current  members, 
who  are  all  national  officials  responsible  for  advising  on 
matters  relating  to  the  authorization  of  veterinary 
medicines  in  their  home  countries,  is  set  out  in  Annex  2. 
The  Committee  elects  its  chairman  from  among  its  members 
by  absolute  majority  and  secret  ballot.  The  term  of  office 
of  the  chairman  is  three  years,  renewable  once  only. 
Following  the  promotion  of  Professor  Arpad  Somogyi  to  new 
responsibilities  within  the  Bundesgesundheitsamt,  Mr 
Jacques  Boisseau,  Director  of  the  Laboratoire  National  des 
Medicaments  Veterinaires  (CNEVA)  at  Fougeres  in  France  was 
elected  chairman  of  the  Committee  in  September  1988. 
The  rules  of  procedure  also  provide  for  two  deputy 
chairmen,  one  of  whom  is  elected  by  the  Committee  in 
accordance  with  the  same  procedure  as  the  chairman,  and 
who  replaces  the  chairman  in  case  of  absence.  The  other  is 
appointed  by  the  Commission  to  transact  routine  business 
on  behalf  of  the  Committee  between  meetings.  In  September 
1988,  Mr  Alastair  Kidd,  Deputy  Director  of  the  Veterinary 
Medicines  Directorate  at  Weybridge,  was  elected  deputy 
chairman,  while  Mr  Fernand  Sauer,  head  of  the 
pharmaceuticals  unit  within  the  Directorate  general  for 
Internal  Market  and  Industrial  Affairs,  continues  to  serve 
as  the  deputy  chairman  appointed  by  the  Commission. 
- 4-2.2  Communication  and  Information 
The  work  of  the  CVMP  is  of  pivotal  importance  in  the 
application  of  the  Community  directives  relating  to 
veterinary  medicines.  Equally,  the  views  of  the  Committee 
are  of  considerable  interest  and  relevance  to  the 
industry,  and  to  others  with  interests  in  this  sector.  In 
these  circumstances,  the  Committee  has  decided  to  aim  for 
the  greatest  possible  transparency  in  respect  of  its  work, 
subject  only  to  the  constraints  imposed  by  the  need  to 
protect  the  confidential  information  submitted  by 
companies  in  their  dossiers  for  applications  for  marketing 
authorization. 
There  are  three  main  aspects  to  this  policy  of 
transparency: 
l.  The  adoption  of  a  press  release  at  the  end  of  each 
meeting. 
2.  The  presentation  of  an  annual  report  on  the  activities 
of  the  Committee. 
3.  The  organization  of  periodic  meetings  between  the 
Committee  and  all  groups  interested  in  the 
authorization  and  control  of  veterinary  medicines, 
including  manufacturers.  consumers,  the  veterinary  and 
pharmacy  professions,  farmers  groups,  etc.  It  is  hoped 
to  organise  the  first  such  meeting  in  the  course  of 
1991. 
In  addition,  active  consideration  is  being  given  to  the 
possible  admission  of  observers  from  consumer  groups  and 
industry  to  those  parts  of  the  meetings  of  the  CVMP  which 
are  concerned  with  questions  of  general  principle; 
The  Commission  and  the  Committee  hope  that  this  policy  of 
transparency  will  contribute  to  a  greater  public  awareness 
and  understanding  of  the  processes  by  which  veterinary 
medicines  are  evaluated  and  authorized  within  the 
Community. 
- 5 -2.3  Harmonization  of  scientific  requirements 
The  authorization  of  veterinary  medicinal  products  in  the 
Community  depends  upon  the  applicant  providing  convincing 
demonstration  of  the  quality,  the  safety  and  the  efficacy 
of  the  veterinary  medicinal  product  concerned. 
Quality  covers  the  verification of  the  ability  of  the 
applicant  to  produce  a  stable  and  homogenous  product,  in 
accordance  with  its  approved  specifications,  on  an 
industrial  scale. 
Safety  currently  covers  three  aspects: 
- the  safety  of  any  residues  of  the  product  for  human 
consumers  of  foodstuffs  of  animal  origin; 
- the  safety  of  the  product  in  the  target  species  of 
animal; 
- the  safety  of  the  product  for  the  animal  holder  and  the 
veterinarian. 
Moreover,  following  the  entry  into  force  on  1  January  1992 
of  Directive  90/676/EEC,  which  amends  the  basic  Directive, 
81/851/EEC,  consideration  will  also  have  to  be  given  to 
the  safety  of  the  product  for  the  environment. 
Efficacy  covers  the  verification  that  the  product  does 
indeed  have  the  effects  claimed  by  the  manufacturer,  for 
example,  for  the  prevention  or  treatment  of  disease,  or 
for  the  increase  in  growth  or  yields  from  the  treated 
animal.  In  addition,  in  the  case  of  a  product  intended  to 
increase  growth  or  yields,  the  efficacy criterion  extends 
to  the  verification  of  the  quality  of  the  foodstuffs 
obtained  from  treated  animals. 
Directive  81/852/EEC  as  amended  by  Directive  87/20/EEC 
sets  out  the  detailed  requirements  for  the  analytical, 
pharmaco-toxicological  and  clinical  tests  and  trials  which 
have  to  be  conducted  before  authorization  can  be  obtained 
for  a  veterinary  medicinal  product. 
With  effect  from  1  July  1987,  the  Council  has  delegated  to 
the  Commission  the  power  to  amend  the  testing  requirements 
set  out  in  Directive  81/852/EEC.  Moreover,  following  the 
adoption  on  13  December  1990  of  Directive  90/677/EEC 
extending  the  scope  of  the  veterinary  medicines  directives 
to  immunological  veterinary  medicinal  products,  the 
Commission  also  has  to  prepare  new  requirements  for  the 
testing  of  immunologicals. 
-6-A  comprehensive  review  of  the  testing  requirements  for  all 
categories  of  veterinary  medicines  is  therefore  being 
undertaken  by  the  Commission  in  close  cooperation  with  the 
CVMP  and  its  various  working  parties.  It  is  anticipated 
that  draft  texts  will  be  available  for  consultation  during 
the  course  of  1991. 
In  addition,  the  working  parties  of  the  CVMP  are  currently 
preparing  a  series  of  guidelines  to  complement  the 
detailed  legislative  rules.  Further  information  is  given 
in  section  2.5  below. 
2.4  Standard  application dossier 
In  order  to  progress  towards  the  free  movement  of 
veterinary  medicinal  products  within  the  Community,  it  is 
important  to  supplement  the  detailed  work  being  undertaken 
on  the  harmonization  of  legislative  requirements  by  action 
of  an  administrative  nature  which  ensures  that  the  same 
application  dossier  is  acceptable  to  all  Member- States.  A 
first  step  in  this  direction  was  taken  with  the 
publication  of  a  "Notice  to  Applicants"  in  1989  which,  in 
addition  to  providing  guidance  on  the  use  of  the  two 
Community  authorization  procedures,  contains  the  basic 
structure  of  a  harmonized  standard  Community  application 
for  authorization  for  veterinary  medicinal  products.  This 
notice  to  applicants  is  published  in  Volume  V of  "The 
Rules  Governing  Medicinal  Products  in  the  European 
Community",  which  contains  the  rules  currently  in  force 
for  veterinary  medicinal  products  (Catalogue  Number 
CB-55-89-972-EN). 
A detailed  review  of  the  "Notice  to  Applicants"  will  be 
required  during  1991  to  take  account  of  the  changes  in  the 
legal  requirements  for  the  testing  of  veterinary  medicines 
and  the  entry  into  force  of  the  reformed  "Multi-State" 
procedure. 
-7-2.5  Working  Parties  of  the  CVMP 
In  order  to  provide  specialist  support  in  a  number  of 
priority scientific areas,  the  CVMP  has  established  a 
number  of  working  parties;  safety  of  residues  (1984); 
efficacy  of  veterinary  medicines  (1988);  veterinary 
pharmacovigilance  (1989);  immunological  veterinary 
medicinal  products  (1990).  These  working  parties 
constitute  an  integral  part  of  .the  CVMP  and  serve  both  to 
reinforce  the  expertise  available  to  the  Committee  and  to 
integrate  a  wide  range  of  national  experts  into  Community 
activities. 
One  of  the  major  tasks  of  the  working  parties  is  the 
preparation of  guidelines  which  provide  detailed  but 
flexible  guidance  for  the  industry  on  the  conduct  of  the 
various  tests  and  trials  necessary  to  obtain  authorization 
for  a  veterinary  medicinal  product.  Although  these 
guidelines  are  not  binding,  compliance  with  them  provides 
the  industry  with  a  guarantee  the  the  results  of  the 
various  studies  will  be  accepted  as  valid  by  the 
regulatory  authorities  of  the  12  Member  States. 
2.5.1  Working  party  on  the  safety  of  residues 
The  working  party  on  the  safety  of  residues  has  been 
chaired  by  Dr  Dieter  Arnold  of  the  Bundesgesundheitsamt 
since  September  1988.  The  working  party  has 
responsibility  for  advising  the  CVMP  on  general 
principles  for  the  safety  evaluation  of  residues  of 
veterinary  medicines  in  foodstuffs  of  animal  origin. 
A comprehensive  draft  guideline  on  the  safety evaluation 
of  new  veterinary  medicinal  products,  with  particular 
emphasis  on  the  evaluation  of  the  safety of  residues  was 
circulated  to  interested  parties  for  comments  during 
1990,  and  after  consideration  of  the  comments  received, 
is  expected  to  be  definitively  adopted  in  the  course  of 
1991.  (111/3897/88) 
In  addition,  the  working  party  has  responsibility  for 
undertaking  the  evaluation  of  the  safety of  individual 
compounds  which  are  authorized  for  use  in  food  producing 
animals  within  the  Community,  and  in  preparing 
recommendations  for  maximum  residue  limits  (MRLs)  in 
respect  of  the  compounds  concerned,  taking  into  account 
evaluations  which  may  have  been  undertaken  by  the  Codex 
Alimentarius.  This  important  aspect  of  the  work  of  the 
CVMP  is  described  in  detail  in  section  5  below. 
-8-2.5.2  Working  Party  on  the  Efficacy  of  Veterinary  Medicines 
The  working  party  on  efficacy,  which  is  chaired  by  Mr 
Alastair  Kidd  from  the  United  Kingdom,  is  responsible 
for  preparing  guidelines  on  the  demonstration  of  the 
efficacy of  veterinary  medicines.  During  1990,  seven 
guidelines  were  sent  out  for  consultation  covering; 
- general  principles  for  the  demonstration  of  efficacy 
and  the  conduct  of  clinical  trials; 
- preparation  of  veterinary  clinical  expert  reports; 
- fixed  combination  products; 
- the  demonstration  of  secondary  pharmacodynamic 
actions; 
- antimicrobials; 
anthelmintics  for  the  bovine  and  ovine  species; 
- performance  enhancers. 
In  addition,  a  number  of  other  guidelines  are  at  various 
stages  of  preparation,  and  are  expected  to  be  released 
for  comment  during  1991.  including 
- conduct  of  pharmacokinetic  studies; 
- conduct  of  bioequivalence  studies: 
- drugs  acting  on  the  central  nervous  system; 
- efficacy  of  sedatives  and  hypnotics; 
- efficacy  of  products  for  use  in  farmed  fish; 
- glucoco-corticoids  and  non-steroidal  anti-inflammatory 
compounds; 
- products  for  use  in  minor  species; 
- anthelmintics  for  use  in  species  other  than  the  bovine 
or  ovine; 
- intra-mammary  preparations  for  the  treatment  of 
clinical  and  sub-clinical  mastitis  in  cattle; 
- teat  dips  for  the  prevention  of  mastitis  in  lactating 
cows; 
- products  intended  to  treat  Varroa  Jacobsoni and 
Acarapis  lt'oodi Parasitosis in  bees 
- products  for  zootechnical  purposes 
anti-coccidials  for  the  treatment  of  coccidiosis  in 
chickens 
-9-2.5.3  Working  party  on  veterinary  pharmacovigilance 
The  term  pharmacovigilance  covers  the  collection  and 
evaluation  of  reports  of  adverse  drug  reactions  to 
medicinal  products  and  the  adoption  of  appropriate 
regulatory  action  in  response.- Although 
pharmacovigilance  in  the  human  medicines  sector  is  a 
well  established  activity,  in  the  veterinary  medicines 
sector,  it  is  a  relatively  new  area  of  activity. 
The  working  party  on  veterinary  pharmacovigilance  has 
three  major  objectives; 
- to  agree  a  common  methodology  for  the  collection  and 
evaluation  of  adverse  reactions  to  veterinary 
medicines  in  animals  among  the  Member  States  which 
already  have  a  national  pharmacovigilance  system 
(currently  Germany,  France,  Ireland,  Italy  and  the 
United  Kingdom) 
to  provide  technical  advice  and  assistance  for  any 
other  Member  State  wishing  to  establish  such  a  system; 
to  provide  a  forum  for  the  exchange  of  information  and 
discussion  of  specific  problems  concerning  adverse 
reactions  to  particular  products. 
Up  to  the  end  of  1990,  the  working  party  was  chaired  by 
Dr  Rinette  Julicher of  the  Netherlands. 
One  of  the  first  actions  of  the  new  working  party  was  to 
create  a  Community  wide  rapid  alert  system  for  the 
exchange  of  information  about  urgent  pharmacovigilance 
actions.  The  group  is  also  preparing  a  comprehensive 
framework  for  cooperation  at  Community  level  in  this 
area  and  a  guideline  setting  out  the  responsibilities  of 
the  industry  for  the  collection,  evaluation  and 
reporting  of  information  about  adverse  reactions  to 
veterinary  medicines. 
2.5.4  Working  party  on  immunological  veterinary  medicinal 
products 
In  anticipation  of  the  decision  by  the  Council  to  extend 
the  scope  of  the  veterinary  medicines  directives  to 
cover  vaccines  and  sera,  the  CVMP  decided  to  set  up  a 
specific  working  party  on  immunological  veterinary 
medicinal  products. 
-10-Currently  chaired  by  Professor  Leunen,  from  Belgium, 
this  working  party  brings  together  experts  on  all 
aspects  of  the  evaluation  of  veterinary  vaccines.  The 
working  party  has  three  main  functions; 
- the  evaluation  of  individual  applications  for 
marketing  authorization  for  immunological  veterinary 
medicinal  products  derived  from  biotechnology,  which 
are  already  being  submitted  in  accordance  with 
Directive  87/22/EEC; 
- advising  the  Commission  on  the  detailed  test 
requirements  necessary  to  show  the  quality,  safety  or 
efficacy of  veterinary  immunologicals; 
- preparing  general  g~idelines  on  the  structure  of  the 
application dossier  for  this  type  of  product  and  the 
conduct  of  the  various  tests  and  trials. 
2.6  Quality  of  Veterinary  Medicinal  Products 
The  requirements  for  the  quality  of  veterinary  medicinal 
products,  which  are  set  out  in  Part  I  of  the  Annex  to 
Directive  81/852/EEC,  are  substantially  the  same  as  the 
quality  requirements  for  medicinal  products  for  human 
use,  as  set  out  in  Directive  75/318/EEC.  For  this  reason. 
the  CVMP  has  decided  not  to  establish  a  separate  working 
party  on  the  quality  of  veterinary  medicines. 
However  in  March  1990,  the  CVMP  held  a  special  ad  hoc 
meeting  on  the  quality  of  veterinary  medicinal  products 
to  consider  subsequent  developments  in  the  quality 
requirements  for  human  medicine  and  their  relevance  to 
the  veterinary  sector.  In  principle,  the  Committee  agreed 
that  the  quality  requirements  set  out  in  the  notice  to 
applicants  for  medicinal  products  for  human  use 
concerning  the  presentation  of  Part  II  of  the  Dossier  and 
the  Quality  expert  report  were  applicable  to  veterinary 
medicines  with  only  minor  detailed  amendments.  (See  the 
Rules  Governing  Medicinal  products  in  the  European 
Community,  Volume  II,  Catalogue  No  CB-55-89-293-EN-C). 
- l 1 -In  addition,  the  Committee  agreed  that  the  following 
quality  guidelines  established  by  the  Committee  for 
Proprietary  Medicinal  Products  could  in  principle  be 
applied  to  veterinary  medicinal  products; 
- development  pharmaceutics  and  process  validation 
- chemistry  of  active  ingredients; 
- stability  tests  on  active  ingredients  and  finished 
products: 
- quality  of  herbal  remedies; 
- analytical  validation. 
The  Committee  has  also  subsequently  agreed  that  the 
European  Drug  Master  File  procedure  established  for 
medicinal  products  for  human  use  will  be  applied  by  Member 
States  in  the  same  way  to  veterinary  medicinal  products. 
However,  the  Committee  has  decided  to  elaborate  a 
separate  guideline  on  the  quality  requirements  for 
medicinal  premixes  intended  for  use  in  the  subsequent 
manufacture  of  medicated  feedingstuffs. 
2.7  Good  manufacturing  practices  for  veterinary  medicinal 
products 
Following  the  entry  into  force  of  Directive  90/676/EEC, 
all  production  of  veterinary  medicinal  products  will  have 
to  be  undertaken  in  acordance  with  the  principles  of  Good 
Manufacturing  Practices  (GMPs).  The  Council  has  delegated 
to  the  Commission,  in  accordance  with  the  so-called 
'regulatory  committee  procedure',  the  power  to  adopt  the 
principles  and  guidelines  of  good  manufacturing  practices 
which  must  be  complied  with. 
In  preparation  for  the  entry  into  force  of  these  new 
requirements,  the  Committee  has  undertaken  a  survey  of  the 
arrangements  within  Member  States  for  the  inspection  of 
manufacturers  of  veterinary  medicinal  products.  It  emerged 
that  the  arrangements  for  the  inspection  and  control  of 
manufacturers  of  veterinary  medicines  were  in  most  Member 
states  the  same  as  the  arrangements  for  the  control  of 
medicinal  products  for  human  use.  As  a  consequence  of  that 
survey,  it  was  agreed  that  it  would  not  be  appropriate  to 
prepare  a  special  Community  code  of  good  manufacturing 
practices  for  veterinary  medicinal  products.  Instead,  the 
EEC  guide  to  Good  Manufacturing  Practices  (Volume  IV  of 
the  Rules  Governing  Medicinal  Products  within  the  European 
Community)  will  be  completed  by  two  further  annexes 
setting  out  the  specific  requirements  for  GMPs  for 
- 1 2-veterinary  medicinal  products  and  for  immunological 
veterinary  medicinal  products.  These  two  annexes  are  being 
prepared  jointly  by  the  CVMP  and  the  Commission  Working 
Party  of  Pharmaceutical  Inspectors,  and  will  be  circulated 
for  comments  shortly,  together  with  the  text  of  the  Draft 
Directive  setting  out  the  principles  of  GMPs  for  the 
manufacture  of  veterinary  medicinal  products. 
2.8  Review  of  old  veterinary  medicines 
In  accordance  with  Article  52  of  Directive  81/851/EEC,  the 
Member  States  are  required  to  apply  progressively  the 
requirements  laid  down  in  Directives  81/851/EEC  and 
81/852/EEC  to  old  veterinary  medicinal  products  which  were 
first  placed  on  the  market  by  virtue  of  earlier 
provisions.  This  review  should  be  completed  before  1 
October  1991. 
In  order  to  verify  the  progress  of  the  review,  the 
Committee  has  conducted  a  pilot  questionnaire  on  the 
outcome  of  the  review  in  the  case  of  antibiotics  of  the 
tetracycline  group.  The  Committee  has  now  decided  to 
conduct  a  more  wide-ranging  exercise  covering  a  number  of 
other  widely  used  compounds. 
In  addition,  the  Committee  has  established  a  network  of 
informal  bilateral  contact  points  in  the  Member  States  who 
are  able  to  answer  questions  from  the  other  Member  States 
about  the  status  and  outcome  of  the  review  in  specific 
cases. 
Moreover,  in  accordance  with  Articles  20  and  22  of 
Directive  81/851/EEC,  it  is  possible  to  refer  specific 
cases  for  examination  by  the  Committee,  in  particular 
where  Member  States  have  adopted  divergent  decisions  as  a 
result  of  the  review.  However,  this  possibility  has  not 
yet  been  used. 
2.9  Hormones 
In  accordance  with  Article  3(a)  of  Directive  88/146/EEC, 
the  CVMP  adopted  an  opinion  on  a  list  of  products 
containing  oestradiol  176,  testosterone  and  progesterone 
which  may  be  authorized  by  Member  States  for  the 
therapeutic  treatment  of  a  fertility  problem  in  individual 
farm  animals  on  10  September  1987,  which  was  subsequently  · 
transmitted  by  the  Commission  to  the  Permanent  Veterinary 
Committee  for  consideration. 
- I 3-In  addition,  in  accordance  with  Article  2(1)(b)  of 
Directive  88/299/EEC,  the  CVMP  is  required  to  give  a 
further  opinion  on  a  list of  products  containing  hormonal 
compounds  which  may  be  authorized  by  Member  States  in  view 
of  the  synchronization  of  oestrus.  the  interruption  of 
unwanted  pregancy  and  the  preparation  of  donors  and 
recipients  for  artificial  insemination. 
The  preparation  of  this  second  opinion  was  entrusted  to  an 
ad  hoc  working  party  chaired  by  Dr  Cyril  0'  Sullivan  from 
Ireland.  Following  consultation  with  Member  States  and  the 
companies  concerned,  in  January  1991  the  Committee  adopted 
its  opinion,  which  will  shortly  be  transmitted  to  the 
Permanent  Veterinary  Committee  (III/3860/90  final). 
3.  THE  MULTI-STATE  PROCEDURE 
The  Multi-State  procedure  was  established  by  Chapter  IV  of 
Directive  81/851/EEC.  It  enables  a  company  which  has 
obtained  authorization  for  a  veterinary  medicinal  product 
in  one  Member  State  to  seek  the  extension  of  that 
authorization  to  at  least  five  of  the  other  Member  States, 
using  a  procedure  which  is  based  upon  the  concept  of  mutual 
recognition  of  national  marketing  authorizations. 
Upon  receipt  of  a  valid  application.  the  five  or  more 
Member  states  concerned  have  120  days  either  to  accept  the 
initial  authorization  or  to  put  forward  a  reasoned 
objection  explaining  why  authorization  cannot  be  granted. 
If  objections  are  received,  the  Committee  then  has  a 
further  period  of  60  days  to  give  an  opinion  on  whether  or 
not  the  product  satisfies  the  requirements  for 
authorization  laid  down  in  Di:ectives  81/851/EEC  and 
81/852/EEC.  This  opinion  is  not  binding  on  Member  States. 
but  within  a  further  period  of  30  days,  the  Member  States 
must  indicate  what  action  they  intend  to  take  on  the 
opinion  of  the  Committee. 
In  principle,  this  procedure  offers  a  number  of  advantages 
to  a  company  which  wishes  to  place  a  product  on  the  market 
of  the  majority  of  the  Member  States,  in  particular  the  use 
of  a  single  common  file  for  all  Member  States  concerned, 
the  simplification  of  administrative  and  linguistic 
requirements  and  strict  respect  for  time  limits  during  the 
evaluation  of  applications. 
- l 4-However,  in  practice  the  procedure  has  been  rarely  used. 
The  CVMP  has  given  an  opinion  on  one  application,  for  a 
product  originally authorized  by  France,  which  concerned 
all  eleven  of  the  other  Member  States.  Although  certain 
administrative  difficulties  arose  duririg  the  consideration 
of  the  application,  which  concerned  one  Member  State  in 
particular,  the  CVMP  adopted  a  favourable  opinion  on  the 
application  in  March  1988,  and  the  product  has  iubsequently 
been  authorized  by  all  eleven  Member  States.  At  the  present 
time  a  further  five  applications  are  pending,  and  should  be 
the  subject  of  an  opinion  of  the  Committee  during  1991. 
In  the  course  of  1990,  the  Committee  undertook  a  detailed 
review  of  the  "Multi-State''  procedure  and  introduced  a 
number  of  administrative  changes.  The  new  guidance  for  the 
use  of  the  procedure  is  set  out  in  Annex  3. 
Following  the  adoption  of  Directive  90/676/EEC,  further 
changes  will  be  made  to  the  procedure  from  1992  onwards,  in 
particular  the  reduction  of  the  threshold  number  of  Member 
States  from  five  to  two  and  the  introduction  of  a  right  to 
a  hearing  for  companies  using  the  procedure. 
It  must  be  hoped  that  as  a  result  of  these  various  changes. 
the  procedure  will  prove  attractive  to  the  industry  and 
that  a  sufficient  number  of  dossiers  will  be  received  to 
test  seriously  the  feasibility  of  the  'mutual  recognition' 
approach  as  an  option  for  the  future  arrangements  for  the 
authorization  of  veterinary  medicines  within  the  Community. 
- 1 5 -4.  THE  CONCERTATION  PROCEDURE 
4.1  Scope  of  the  concertation  procedure 
The  legal  rules  governing  the  special  Community  procedure 
are  set  out  in  Council  Directive  87/22/EEC.  The  objective 
of  the  procedure  is  to  enable  questions  relating  to  the 
quality,  safety  and  efficacy  of  medicinal  products 
developed  by  means  of  new  biotechnology  processes  and 
other  high  technology  medicinal  products  to  be  resolved  at 
Community  level  within  the  CVMP  before  any  national 
decision  is  reached  concerning  a  marketing  authorization. 
The  concertation  procedure  is  obligatory  for  all  medicinal 
products  developed  by  means  of  the  following 
biotechnological  processes  (List  A of  the  Annex  of 
Directive  87/22/EEC): 
- recombinant  DNA  technology 
- controlled expression  of  genes  coding  for  biologically 
active  proteins  in  prokaryots  and  eukaryots,including 
transformed  mammalian  cells 
- hybridoma  and  monoclonal  antibody  methods 
In  particular,  it  should  be  noted  that  although  harmonized 
Community  rules  for  immunological  veterinary  medicinal 
products  have  not  yet  entered  into  force,  applications  for 
immunological  veterinary  medicinal  products  produced  using 
the  above  biotechnological  processes  must  be  referred  to 
the  Committee  for  an  opinion  in  accordance  with  Directive 
87/22/EEC. 
During  1990  some  uncertainty  arose  about  the  scope  of 
application  of  List  A  in  the  case  of  certain  techniques 
used  in  the  manufacture  of  immunological  veterinary 
medicinal  products.  The  CVMP  is  currently  preparing 
detailed  guidance  on  the  interpretation  and  application  of 
list  A  to  gene  deletion  techniques  and  the  use  of 
hybridoma  and  monoclonal  antibodies  for  selection  and 
purification of  vaccine  strains  or  of  the  finished 
product.  In  the  meantime,  companies  considering  submission 
of  applications  for  such  products  are  advised  to  contact 
the  regulatory  authorities  of  the  Member  States  at  an 
early  stage  to  determine  whether  a  reference  to  the  CVMP 
will  be  required. 
- 16-In  addition,  applicants  for  marketing  authorization  for 
the  following  groups  of  products  may  request  that  the 
application  be  considered  under  the  concertation  procedure 
(List  B  of  the  Annex  of  Directive  87/22/EEC): 
- medicinal  products  developed  by  other  biotechnological 
processes  which  constitute  a  significant  innovation; 
- medicinal  products  administered  by  means  of  new  delivery 
systems  which  constitute  a  significant  innovation; 
- medicinal  products  containing  a  new  substance  or  an 
entirely  new  indication  which  is  of  significant 
therapeutic  interest; 
- new  medicinal  products  based  on  radio-isotopes  which  are 
of  significant  therapeutic  interest; 
- medicinal  products  the  manufacture  of  which  employs 
processes  which  demonstrate  a  significant  technical 
advance  such  as  2-dimentional  electro-phoresis  under 
micro-gravity. 
The  timetable  for  the  concertation  procedure  is  based  on 
the  requirements  of  Article  8  of  Directive  81/851/EEC. 
Since  the  applications  relate  to  complex  processes  which 
are  deemed  to  be  exceptional,  the  rapporteur,  in 
establishing  the  period  for  review,  usually  extends  the 
time  period  of  120  days  to  include  the  additional  90  days 
provided  for  in  exceptional  cases  by  the  directive. 
4.2  Evaluation  of  applications  within  the  CVMP 
The  initial  evaluation  of  an  application  is  undertaken  by 
the  rapporteur  Member  State.  The  assessment  report  of  the 
rapporteur  is  circulated  to  all  Member  States,  who  make 
their  own  comments  and  add  any  further  questions.  The 
Committee  then  discusses  all  the  questions  and  comments 
received  and  prepares  a  complete  list  of  questions  which 
is  presented  to  the  company.  At  this  point  the  clock  stops 
until  the  company  has  presented  a  single  consolidated 
response  to  all  the  questions  raised. 
Thereafter,  the  rapporteur  prepares  a  second  updated 
assessment  report  which  is  again  circulated  to  all  Member 
States  for  comment,  and  discussed  by  the  Committee.  If  the 
Committee  considers  that  the  company  has  presented 
satisfactory replies  to  all  the  questions,  it  will  then 
adopt  a  faourable  opinion.  However,  if  the  replies  are 
considered  unsatisfactory,  the  Committee  identifies  a  list 
- 1 7 -of  outstanding  problems  and  the  company  is  given  a  final 
opportunity  to  respond,  either  in  writing  or  at  a  hearing, 
before  the  Committee  adopts  its  opinion. 
The  opinion  of  the  Committee  is  not  binding,  but  Member 
States  are  obliged  to  inform  the  Committee  within  30  days 
of  what  action  they  have  taken  on  the  opinion. 
4.3  Use  and  outcome  of  the  concertation  procedure 
Since  Directive  87/22/EEC  entered  into  force  on  1  July 
1987,  a  total  of  8  applications  have  been  received  under 
the  concertation  procedure,  six  of  which  have  concerned 
immunological  veterinary  medicinal  products  derived  using 
biotechnological  processes  and  two  have  been  for  products 
containing  recombinant  bovine  somatotropin  (BST). 
Applications  for  immunological  products  are  systematically 
referred  to  the  immunologicals  working  party  for  advice 
before  their  consideration  by  the  full  Committee.  Other 
applications  under  the  concertation  procedure  are  treated 
by  the  CVMP  itself,  although  if  necessary  an  ad  hoc 
specialist  working  party  may  be  set  up  to  provide  advice 
on  specific  questions. 
To  date,  the  Committee  has  adopted  opinions  in  respect  of 
three  applications  and  five  remain  pending.  The  three 
opinions,  all  of  which  were  favourable,  concern  the 
following  immunological  veterinary  medicinal  products: 
- TOLVID.  from  the  Upjohn  Company;  opinion  adopted  on  30 
June  1989  but  subsequently  withdrawn,  following  the 
withdrawal  of  the  application  by  the  company  in  all  12 
Member  states; 
- NOBI-VAC  AUJESZKY,  from  the  Intervet  Company;  opinion 
adopted  on  28  November  1990; 
- NOBI-PORVAC  AUJESZKY  LIVE,  from  the  Intervet  Company, 
opinion  adopted  on  28  November  1990. 
The  examination  of  the  two  separate  applications 
concerning  bovine  somatotropin  from  Eli  Lilly  and  Monsanto 
has  presented  a  particular  challenge  to  the  Committee, 
partly  because  of  the  sheer  volume  of  data  submitted  in 
support  of  the  applications,  and  partly  because  of  the 
difficulty  in  reconciling  the  legitimate  requests  for 
public  information  about  these  products  with  the 
constraints  imposed  by  the  requirements  of  commerial 
confidentiality.  In  order  to  respond  to  the  latter 
concerns,  the  Committee  has  decided  that  once  its 
evaluation  is  complete  it will  request  the  Commission  to 
publish  the  opinion  on  each  of  these  applications  and  it 
will  also  prepare  a  more  detailed  assessment  report  on 
each  of  the  products  concerned. 
-18-4.4  Hearings 
Directive  87/22/EEC  provides  the  applicant  company  with  a 
right  to  a  hearing  before  the  Committee  adopts  its  final 
opinion  on  an  application.  To  date,  the  Committee  has  held 
four  such  hearings  with  pharmaceutical  companies.  In  the 
light  of  experience,  the  Committee  has  issued  new  guidance 
for  companies  on  the  conduct  of  hearings  (Annex  4). 
It  is  important  to  note  that  hearings  take  place  in  a 
multi-lingual  environment  and  that  simultaneous  technical 
interpretation during  the  hearing  is  necessary.  Given  the 
heavy  workload  of  the  Committee,  the  time  available  for 
hearings  is  limited.  Therefore,  a  hearing  cannot  be  used 
as  an  opportunity  to  resolve  extensive  technical  points  or 
to  resolve  deficiencies  in  the  dossier.  Rather,  the 
hearing  provides  an  opportunity  for  the  applicant  to 
present  its  point  of  view  on  basic  questions  concerning 
the  evaluation  of  the  benefits  and  risxs  presented  by  a 
particular  product  once  all  the  technical  aspects  of  the 
file  have  been  clarified. 
For  this  reason,  the  CVMP  will  not  schedule  the  date  for  a 
hearing  until  replies  have  been  received  from  the  company 
to  all  outstanding  questions,  and  the  issues  for 
discussion  at  the  hearing  have  been  fully  clarified. 
-19-5.  EVALUATION  OF  THE  SAFETY  OF  RESIDUES 
5.1  Introduction 
The  administration  of  veterinary  medicinal  products  to 
food  producing  animals  is  likely  to  result  in  very  small 
quantities  of  residues  of  the  product  or  its  metabolites 
being  present  in  foodstuffs  of  animal  origin.  In  order  to 
ensure  the  proper  protection  of  public  health  within  the 
Community,  it  is  therefore  necessary  to  ensure  that  this 
residue  is  maintained  at  as  low  a  level  as  is  possible  and 
is  without  risk  for  the  consumer  of  foodstuffs  of  animal 
origin.  Historically,  the  traditional  approach  to  the 
regulation  of  residues  was  the  based  on  a  concept  of  zero 
residue.  However,  this  concept  is  a  function  of  the 
sensitivity of  the  analytical  methods  used  to  detect 
residues,  and  in  recent  years  considerable  advances  in 
analytical  methodology  have  made  it  possible  to  detect 
residues  at  ever-lower  levels. 
For  this  reason,  in  February  1989,  the  Commmission 
proposed  that  the  Community  should  be  empowered  to  adopt 
maximum  residue  limits  (MRLs)  for  the  individual  compounds 
used  in  food  producing  animals  after  a  scientific 
evaluation  of  the  safety  of  the  compound  concerned  to  be 
undertaken  by  the  CVMP. 
On  26  June  1990,  following  a  favourable  opinion  from  the 
European  Parliament,  the  Council  adopted  Regulation  (EECl 
2377/90  laying  down  a  Community  procedure  for  the 
establishment  of  maximum  residue  limits  of  veterinary 
medicinal  products  in  foodstuffs  of  animal  origin.  Once 
this  regulation  comes  into  effect,  on  1  January  1992, 
Member  States  will  not  be  able  to  authorize  any  new  active 
substance  for  use  in  veterinary  medicine  unless  a  Maximum 
Residue  Limit  has  been  agreed  by  the  Community.  In 
addition,  the  Community  must  establish  MRLs  for  all  active 
compounds  currently  authorized  for  use  in  food  producing 
animals  over  the  five  year  period  1992-1996. 
In  order  to  prepare  for  the  entry  into  force  of  the  new 
regulation,  the  CVMP  is  currently  preparing  a  "Notice  to 
Applicants"  explaining  how  to  prepare  and  present 
applications  for  the  establishment  of  MRLs  and  a  timetable 
for  the  evaluation  of  existing  compounds. 
-20-However,  even  before  the  adoption  of  the  new  regulation, 
the  CVHP,  had  begun  consideration  of  the  general 
principles  to  be  applied  in  the  safety  evaluation  of 
residues,  and  had  begun  the  evaluation  of  certain  widely 
used  priority  compounds.  In  November  1990,  the  CVHP 
approved  recommendations  for  HRLs  for  21  compounds.  These 
recommendations  are  set  out  in  Annex  5  of  this  report,  and 
copies  of  the  summaries  of  the  evaluations  of  these 
compounds  undertaken  by  the  CVMP  are  available  in  English 
or  French  upon  request  from  the  Pharmaceutical  Unit  of  the 
Commission. 
Written  comments  are  invited  from  industry  and  other 
interested  parties  on  these  recommendations  for  MRLs.  Any 
comment  should  be  addressed  in  writing  to  the  Secretariat 
of  the  CVMP,  at  the  address  given  in  Annex  2,  to  arrive 
before  1  September  1991.  Subject  to  any  further  comments 
from  Member  States  or  other  interested  parties,  it  is  the 
intention  of  the  Commission  to  present  these  proposals  for 
adoption  in  accordance  wiith  Council  Regulation  2377/90  as 
soon  as  possible  after  1  January  1992. 
5.2  Current  procedure  for  the  evaluation  of  residues  within 
the  CVMP 
Within  the  CVHP,  the  evaluation  of  the  safety  of  residues 
is  undertaken  by  the  residues  working  party,  which 
includes  experts  from  all  Member  States.  Any  member  of  the 
working  party  may  propose  that  a  particular  compound 
should  be  the  subject  of  a  review  by  the  group.  The  group 
as  a  whole  considers  the  list of  compounds  proposed  and 
establishes  a  priority  list. 
The  group  then  appoints  one  of  its  members  to  act  as 
rapporteur  for  the  compound,  and  to  prepare  a  monograph  on 
the  available  data.  In  order  to  avoid  unnecessary 
duplication  of  effort,  the  rapporteur  is  usually  selected 
from  a  Member  State  which  has  recently  reviewed  or  is  in 
the  process  of  reviewing  the  compound  concerned  at 
national  level. 
The  monograph,  including  proposals  for  HRLs,  is  then 
discussed  by  the  whole  group,  and  requests  for 
clarification or  amendment  of  the  monograph  may  be  put  to 
the  rapporteur.  Once  the  group  has  reached  a  consensus  on 
the  evaluation  of  the  compound,  the  rapporteur  prepares  a 
summary  of  the  evaluation  which  is  forwarded  to  the  CVMP 
for  approval  and  then  published  by  the  Commission. 
- 2 l -The  working  methods  of  the  group  have  developed 
informally,  and  are  based  on  administrative  cooperation 
between  Member  States.  Any  necessary  liaison with  the 
commercial  sponsors  of  the  compound  is  normally  un·dertaken 
by  the  administration  of  the  Member  States,  although 
occasionally  a  company  may  be  invited  to  make  a 
presentation  before  the  group.  However,  once  Regulation 
2377/90  has  entered  into  force,  the  work  of  the  group  will 
be  put  on  a  formal  basis,  and  provision  will  be  made  for  a 
formal  hearing  of  the  companies  concerned. 
5.3  The  principles  of  the  safety  evaluation  of  residues 
The  approach  used  by  the  CVMP  and  its  residues  working 
party  for  the  evaluation  of  the  safety  of  residues  is 
broadly  similar  to  the  approach  used  by  other  scientific 
bodies  charged  with  the  safety  evaluation  of  food 
additives  and  contaminants.  In  particular,  there  are  many 
similarities  between  the  methods  used  by  the  CVMP  and  the 
WHO/FAO  Joint  Expert  Committee  on  Food  Additives  which 
undertakes  the  evaluation  of  the  safety  of  residues  of 
veterinary drugs  on  behalf  of  the  Codex  Alimentarius. 
Indeed,  several  members  of  the  CVMP  residues  working  party 
have  been  invited  in  a  personal  capacity  to  serve  on  JECFA. 
Nevertheless,  there  are  certain  specific differences 
between  the  evaluation  of  the  safety  of  residues  of 
veterinary  medicines  and  the  evaluation  of  other  residues 
or  food  additives  or  contaminants.  First,  because  of  the 
properties  of  the  active  substances  used  in  veterinary 
medicine,  account  must  be  taken  not  only  of  the 
toxicological  properties  of  the  compounds  in  the  limited 
sense  of  the  term  (such  as  teratological,  mutagenic  or 
carcinogenic  effects)  but  also  of  their  pharmacological 
properties  and  their  possible  allergenic  potential. 
Moreover,  in  the  case  of  antibiotics  and  similar 
compounds,  the  possibility of  a  microbiological  risk  to 
the  make-up  of  the  human  gut  flora  may  also  need  to  be 
considered.  Secondly,  the  residue  to  which  the  consumer  of 
foodstuffs  of  animal  origin  is  exposed  are  not  necessarily 
the  same  as  the  parent  drug  substance,  since  the  product 
is  metabolised  within  the  treated  animal. 
-22-Following  the  completion of  the  various  pharmacological, 
toxicological  and  other  tests  undertaken  to  demonstrate 
the  safety of  the  compound,  the  first  major  stage  in  the 
process  of  safety evaluation  is  the  establishment  of  the 
acceptable  daily  intake  (ADI).  The  ADI  is  an  estimate  of 
the  residue,  expressed  in  terms  of  micrograms  or 
milligrams  per  kilogram  of  bodyweight,  that  can  be 
ingested  daily  over  a  lifetime  without  appreciable  health 
risk.  It  indicates  a  range  from  zero  to  an  upper  limit. 
The  basis  for  the  calculation  of  the  ADI  is  the 
no-observed-effect  level  (NOEL)  with  respect  to  the  most 
sensitive  parameter  in  the  most  sensitive  appropriate  test 
species,  or  in  some  cases,  in  humans.  A  safety  factor  (SF) 
is  then  applied  to  provide  a  margin  of  safety,  taking  into 
account  the  inherent  uncertainties  in  extrapolating  animal 
toxicity  data  to  human  beings  and  to  take  account  of 
variations  within  the  human  species.  In  selecting  a  safety 
factor,  it  is  usually  assumed  that  human  beings  are  ten 
times  more  sensitive  than  the  test  animal,  and  that  there 
is  a  ten-fold  range  of  sensitivity within  the  human 
species.  Thus,  where  good  quality  data  are  available,  a 
safety  factor  of  100  is  usually  applied,  although  this  may 
be  increased  or  reduced  depending  on  the  nature  and 
quality  of  the  data  available  and  of  the  effects  observed 
in  animals  or  man. 
Where  the  available data  are  sufficient  to  demonstrate 
that  exposure  to  residues  over  several  years  will  not 
present  a  risk  to  health,  but  there .are  insufficient  data 
to  guarantee  safety  over  a  life-time,  a  temporary  ADI  may 
be  accepted,  using  a  higher  safety  factor. 
The  ADI  concept  is  not  applicable  to  substances  for  which 
it  is  not  possible  to  determine  a  NOEL  because  they 
demonstrate  non-threshold  effects.  In  such  cases,  an 
alternative  approach  to  safety  evaluation  applied  on  a 
case  by  case  basis,  having  regard  to·all  the  data 
available. 
Once  the  ADI  has  been  agreed,  it  is  then  necessary  to 
determine  MRLs  for  the  individual  food  commodities 
concerned.  Since  the  ADI  is  related  to  body  weight,  an 
arbitrary  average  human  bodyweight  is  defined  at  60  kg. 
The  ADI  is  therefore  multiplied  by  60  to  give  the  total 
amount  of  residue  which  can  be  ingested  by  a  human  being. 
-23-Moreover,  consideration  also  has  to  be  given  to  the  actual 
levels  of  consumption  of  foods  of  animal  origin.  Since 
accurate  consumption  figures  are  difficult  to  obtain,  and 
there  are  in  any  case  substantial  variations  between 
individual  consumers,  arbitrarily  high  fixed  values  are 
used  to  ensure  the  protection  of  the  majority  of  consumers. 
Thus  for  the  purpose  of  deriving  MRLs  from  the  ADI  it  is 
assumed  that  the  average  person  consumes,  on  a  daily 
basis,  500  g  of  meat  (made  up  of  300  g  of  muscle,  100  g  of 
liver,  50  g  of  kidney  and  50  g  of  fat)  together  with  1.5 
litres  of  milk  and  100  g  of  eggs  or  egg  products.  The 
total  amount  of  residues  present  in  this  daily  food  package 
is  not  allowed  to  excede  the  ADI. 
MRLs  are  then  allocated  to  the  individual  food  commodities 
concerned;  muscle  tissue,  liver,  kidney,  fat,  eggs  and 
milk.  At  this  stage,  account  is  also  taken  of  the  pattern 
of  residue  depletion of  the  compound  through  the  target 
animal,  and  the  possible  lengthy  persistence  of  residues 
in  specific  organs  such  as  the  liver  or  kidneys,  or  at  the 
injection  site.  The  MRLs  allocated  to  animal  tissues 
usually  apply  to  all  species,  unless  otherwise  stated. 
Once  the  process  of  safety evaluation  is  complete,  and 
MRLs  have  been  derived  for  a  particular  compound. 
consideration  is  then  given  to  the  likely  level  of  residue 
which  may  be  expected  to  remain  after  the  use  of  the 
compound  in  accordance  with  good  veterinary  practice,  and 
to  the  availability of  analytical  detection  methods 
suitable  for  use  for  routine  monitoring  purposes.  The  HRLs 
may  be  further  reduced,  but  never  increased,  to  take 
account  of  these  factors. 
Once  MRLs  have  been  allocated,  it  is  then  necessary  to 
determine  withdrawal  periods  during  which  the  target 
animal.  must  not  be  slaughtered,  or  during  which  milk  or 
eggs  must  not  be  taken  for  human  consumption,  which  ensure 
that  residues  from  the  product  concerned  will  not  exceed 
the  MRLs.  Since  the  duration  of  the  withdrawal  period  will 
depend  on  the  individual  pharmaceutical  formulation 
concerned,  withdrawal  periods  are  currently  determined  by 
Member  States  as  part  of  the  overall  process  of  evaluation 
of  the  application  for  marketing  authorization.  The  CVMP 
has  recently  agreed  certain  general  principles  to  be  taken 
into  consideration  for  the  determination  of  withdrawal 
periods  (Annex  6).  and  consideration  is  being  given  to  the· 
preparation  of  more  detailed  guidelines. 
-24-6.  INTERNATIONAL  RELATIONS 
Through  the  intermediary  of  the  Commission,  good  relations 
have  been  established  between  the  CVMP  and  the  Nordic 
Council  of  Medicines.  An  observer  from  the  Nordic  Council 
attends  meetings  of  the  efficacy  working  party  and  a 
regular  exchange  of  guidelines  takes  place. 
Following  the  establishment  of  bilateral  liaison  meetings 
between  the  Commission  and  the  United  States  Food  and  Drug 
Administration,  a  regular  exchange  of  information  takes 
place.  The  expertise  of  the  CVMP  has  been  essential  for  the 
preparation of  the  specific  bilateral  sessions  devoted  to 
veterinary  medicines  which  take  place  at  each  meeting. 
The  expertise  provided  by  the  CVMP  is  also  of  great  value 
in  preparing  coordinated  Community  positions  for  the  annual 
meetings  of  the  Codex  Alimentarius  Committee  on  Residues  of 
Veterinary  Drugs  in  Foods,  and  for  other  international 
contacts  in  this  area. 
7.  PROGRAMME  OF  ACTIVITY  FOR  1991 
In  conclusion  to  this  report  it  appears  appropriate  to 
highlight  some  of  the  major  priorities  for  the  work  of  the 
Committee  during  1991. 
In  addition  to  the  continuing  process  of  evaluation  of 
applications  for  authorization  submitted  under  the 
Community  procedures,  and  continuation  of  the  programme  of 
preparation  of  guidelines,  it  appears  that  the  major  task 
of  the  Committee  will  be  to  prepare  for  the  entry  into 
force  of  the  three  new  legislative  measures  which  were 
adopted  by  the  Council  during  1990  and  which  have  been 
mentionned  at  various  points  earlier  in  this  report. 
Other  priority  tasks  will  include  the  continuing 
implementation  of  the  Committee's  policy  of  transparency, 
the  development  of  veterinary  pharmacovigilance  and  the 
monitoring  of  the  completion  of  the  review  of  old  veterinary 
medicines  in  October  1991. 
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Main  Community  legislative  texts  applicable  to 
veterinary  medicinal  products 
Council  Directive  81/851/EEC  of  28  September  1981  on  the 
approximation  of  laws  of  the  Member  States  relating  to 
veterinary  medicinal  products  (O.J.  No  L  317,  6.11.1981) 
Council  Directive  81/852/EEC  of  28  September  1981  on  the 
approximation  of  laws  of  the  Member  States  relating  to 
analytical,  pharmaco-toxicological  and  clinical  standards  and 
protocols  in  respect  of  the  testing  of  veterinary  medicinal 
products  (O.J.  No  L  317,  6.11.1981) 
Council  Directive  87/20/EEC  of  22  December  1986  amending 
Directive  81/852/EEC  of  28  September  1981  on  the  approximation 
of  laws  of  the  Member  States  relating  to  analytical. 
pharmaco-toxicological  and  clinical  standards  and  protocols  in 
respect  of  the  testing  of  veterinary  medicinal  products  (O.J. 
No  L  15,  17.1.1987) 
Council  Directive  87/22/EEC  of  22  December  1986  on  the 
approximation  of  national  measures  relating  to  the  placing  on 
the  market  of  high-technology  medicinal  products.  particularly 
those  derived  from  biotechnology  (O.J.  N°  L  15,  17.1.1987) 
Council  Regulation  (EEC)  N°  2377/90  of  26  June  1990  laying 
down  a  Community  procedure  for  the  establishment  of  maximum 
residue  limits  of  veterinary  medicinal  products  in  foodstuffs 
of  animal  origin 
(O.J.  No  L  224,  18.8.1990,  p.  l) 
Council  Directive  90/676/EEC  of  13  December  1990  amending 
Directive  81/851/EEC  on  the  approximation  of  laws  of  the 
Member  States  relating  to  veterinary  medicinal  products. 
(O.J.  No  L  373,  31.12.1990,  p.  15) 
Council  Directive  90/677/EEC  of  13  December  1990  extending  the 
scope  of  Directive  81/851/EEC  on  the  approximation  of  laws  of 
the  Member  States  relating  to  veterinary  medicinal  products 
and  laying  down  additional  provisions  for  immunological 
veterinary  medicinal  products. 
(O.J.  No  L  373,  31.12.1990,  p.  26) 
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APPLICATIONS  UNDER  DIRECTIVE  81/851/EEC 
"THE  MULTI-STATE  PROCEDURE" 
1.  The  firm  consults  the  competent  authority of  the  Member  State which 
granted  the  Initial  authorization  and  agrees  any  changes  which  may  be 
necessary  to update  the  dossier. 
2.  The  firm  submits  a  complete  appl lcatlon directly  to  the  competent 
authorities of  at  least  five  Member  States,  Indicating  that  the dossier 
Is  submitted  In  accordance  with Article  17  of  Directive 81/851/EEC,  and 
that  the  Member  State which  granted  the  Initial  authorization  has 
consented  to  the  transmission of  the  documents  directly  by  the  applicant. 
The  CVMP  application  form  Is  annexed  to  the  covering  letter  submitted 
with  the  appl lcatlon. 
A copy  of  the dossier  Is also  transmitted  to  the  Secretariat. 
3.  Upon  receipt  of  Its copy  of  the  dossier,  the  Secretariat  notifies  the 
Member  States of  the  appl !cation  by  telex  (Model  Telex  I)  and  Invites  the 
Member  States directly  concerned  by  the application  to confirm  receipt  by 
telex  or  telefax. 
If  a  Member  State considers  that  the  dossier  Is  not  acceptable  for  the 
purposes of  assessment,  It  immediately  Informs  the Secretariat,  which 
invites  the  appl lcant  to  correct  the  appl lcatlon  (Standard  Form 
Letter  1). 
4.  Once  al 1 Member  States  have  confirmed  receipt  of  the  dossier,  the 
Secretariat  sends  a  second  telex  announcing  the  start of  the  120  period 
allowed  for  the submission of  reasoned objections  In  accordance  with 
Article  18(2)  of  Directive  81/851/EEC  {Model  Telex  II). 
Only  one  telex  per  month  wi  I I  be  sent,  announcing  the start of  the  120 
day  period  for  alI  multi-state  appl !cations that  month. 
An  opinion of  the  CVMP  Is  not  required  If  no  Member  State  has  put  forward 
any  reasoned objection during  the  120  day  period. 
5.  A Member  State sends  any  reasoned  objections  It  may  have  directly  to  the 
appl lcant  with  copies  to  the  Secretariat  and  to  the  Member  State  which 
granted  the  Initial  authorization,  within  the  120  day  period.  The 
Secretariat circulates alI  objections  received  to  alI  Member  States. 
As  soon  as  the first objection  Is  received  from  a  Member  State,  the 
Secretariat  forwards  that  objection  to  the  appl lcant  together  with 
Standard  Form  Letter  2.  The  Secretariat  also  forwards  all  obJections 
subsequently  received  to  the  appl lcant.  If  the  appl lcant  chooses  to 
submit  further  observations  to  the  Committee,  he  Is  expected  to  Include  a 
consolidated  I 1st  of  questions  from  alI  Member  States  together  with  his 
responses. 
- 33  -6.  In  principle,  the opinion of  the  Committee  Is given within  a  further  60 
days.  The  opinion  deals  with  whether,  In  the  I lght  of  the objections put 
forward  by  Member  States,  the  appl lcatlon may  be  accepted. 
However,  the  appl lcant  may  submit  further  observations or  particulars  to 
the Committee  In  response  to  the objections of  the  Member  States.  The 
appl lcant  should  discuss  the  nature of  this  response  with  the  competent 
authority of  the  Member  State which  granted  the  Initial  authorization, 
who  wl  I I  act  as  rapporteur  for  the  Committee.  A single  submission  should 
be  prepared,  covering  alI  the objections  put  forward  (questions  and 
answers). 
The  format  of  the  response  Is  the  same  as  the order  of  presentation of 
the  dossier  and  the  same  rules  as  to  language  apply.  However,  depending 
on  the  Member  States  concerned  by  the  appl lcatlon,  It  wl  II  be  helpful  If 
this  response  can  be  prepared  In  English  and  French. 
This  submission  must  be  transmitted  to  the  Secretariat  and  the  members  of 
the  CVMP  by  name  at  least  30  days  before  the  date of  the  meeting,  In  the 
format  of  the  Notice  to  Appl  lcants. 
In  order  to  allow  time  for  the  preparation of  repl les,  the  appl lcant  may 
request  the  Committee  to  postpone  the  adoption  by  up  to  90  days. 
Any  such  request  must  first  be  agreed  with  the  rapporteur.  It  should  be 
submitted  In  writing  to  the  Secretariat  (telex  or  telefax  may  be  used) 
and  should  contain  a  firm  commitment  from  the  company  as  to  the  date  by 
which  the  additional  Information  wi  I I  be  circulated  to all  Member  States 
and  the  Secretariat. 
7 ..  Although  Directive 81/851/EEC  does  not  give  any  right  to  a  hearing  before 
the  Committee,  the  CVMP  has  decided  that  It  would  be  prepared  to  consider 
a  request  for  a  hearing  where  examination of  the  application  has 
disclosed  the  existence of  important  questions of  Community  Interest  on 
which  It  would  be  useful  to hear  the  point  of  view of  the  appl lcant.  A 
decision  on  such  a  request,  which  should  be  submitted  as  soon  as 
possible,  shal I  be  taken  by  the  Chairman  and  the  two  vice-chairmen  In 
consultation with  the  rapporteur. 
8.  At  the  CVMP  meeting,  the  rapporteur  reports on  the  extent  to  which  the 
reasoned  objections  have  been  resolved.,  The  hearing  (If  any)  takes 
place.  Following  discussion,  the  Committee  prepares  a  draft  opinion,  In 
consultation  with  the  rapporteur.  The  Committee  adopts  the  opinion on 
the  second  day. 
9.  As  soon  as  possible after  the  meeting,  the opinion of  the  Committee  Is 
transmitted  to  the  Permanent  Representations of  the  Member  States. 
Within  30  days  the  Member  States  reach  a  decision on  the  appl fcatfon  for 
marketing  authorization,  and  Inform  the  Committee  thereof. 
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Notes  for  guidance 
on  the  conduct  of  hearings  before  the  Committee 
In  the  light  of  the  experience  acquired,  the  Committee  for 
Veterina·ry  Medicinal  Products  has  decided  to  issue  further 
guidance  to  assist  applicants  in  the  preparation  of  oral 
hearings  before  the  Committee.  This  guidance  should  be  read 
together  with  the  guidance  given  in  Part  I  I  .  Section  5  of  the 
notice  to  applicants. 
1.  At  least  four  weeks  before  the  date  on  which  the  Committee 
proposes  to  consider  the  application; 
the  applicant  must  indicate  in  writing  to  the 
Secretariat  ;.;hetttcr  or  not  he  wishes  to  appear  for  a 
he a r i n g  be f o r· e  t he  Com m  i t tee .  Any  r e que s t  f o r 
audio-visu.1l  eqtJipment  must  also  be  made  at  this  time. 
the  applicant  must  circulate  in  writing  to  all  Member 
States  and  the  Commission  any  additional  information 
'which  he  wishes  to  be  considered  in  connection  with  the 
hearing.  A  covering  letter  should  clearly  indicate  the 
name  of  the  pr·oduct  concerned.  should  summarise  the 
additional  information  submitted  and  its  relationship 
with  the  outstanding  questions  of  the  Committee  and 
should  indicate  that  it  is  for  use  in  connection  with 
the  CVHP  hearing.  In  the  event  that  this  information  is 
voluminous.  the  applicant  should  consider  requesting  a 
postponement  of  the  hearing,  to  enable  proper 
consideration  of  the  information.  The  Committee  also 
reserves  the  right  to  disregard  such  information  or  to 
require  a  postponment  of  the  hearing  if  insufficient 
time  is  allowed  for  the  consideration  of  the 
information. 
2.  At  least  one  week  before  the  hearing  the  applicant  provides 
the  Secretariat  with  a  definitive  list of  the  names  and 
addresses  of  the  representatives  of  the  company  for  the 
hearing.  For  security  reasons,  proof  of  identity  must  be 
provided  to  gain  access  to  Commission  buildings. 
- 35  -3.  nefore  the  start  of  the  hearing:  applicants  are  advised  to 
arrive  30  minutes  before  the  scheduled  start  of  their 
hearinq.  They  should  bring  with  them  3~  hard  copies  of  any 
visual  materials  for  use  by  the  interpreters  and  members 
of  the  Committee.  Each  page  of  such  materials  must  be 
clearly  numbered  to  permit  rapid  identification  of  copies 
of  individual  slides,  in  particular  by  the  interpreters. 
Care  should  be  taken  to  ensure  that  visual  materials  are 
legible  at  a  distance  of  25  metr·es. 
-1.  Conduct  of  the  hearing:  hearings  will  usually  be  conducted 
in  the  following  sequence: 
the  Chairman  will  invite  the  representatives  of  the 
applicant  to  introduce  themselves: 
the  applicant  will  be  invited  to  make  a  brief  general 
presentation  of  the  product,  which  should  not  excede  10 
minutes.  At  this  stage  the  applicant  should  not  go  into 
detail  on  the  answers  to  the  outstanding  questions  of 
the  Committee. 
the  chairman  will  then  invite  the  rapporteur  to  put  the 
outstanding  questions  of  the  Committee,  one  at  a  time, 
usually  in  the  order  quality,  safety,  efficacy.  After 
each  answer  from  the  company,  an  opportunity  will  be 
given  to  the  other  Member  States  to  ask  supplementary 
questions  before  moving  on  to  the  next  question. 
at  the  end  of  the  hearing,  the  applicant  will  be  asked 
to  withdraw  while  the  Committee  considers  its  opinion 
which  will  be  sent  in  writing  to  the  company. 
5.  References  to  specific  studies  when  referring  to  specific 
studies  or  test  results,  the  representatives  of  the 
company  should  state  clearly  whether  these  were  contained 
in  the  original  submission.  in  the  initi~l  replies  of  the 
company  to  the  questions  put  by  the  Committee  or  in  a 
further  submission  which  may  have  been  made  in  preparation 
for  the  hearing. 
6.  Introduction  of  new  information  during  the  hearing  the 
Committee  wishes  to  discourage  companies  in  the  strongest 
possible  terms  from  providing  new  information  only  at  the 
hearing.  Where  such  information  is  provided,  the  Committee 
reserves  the  right  either  to  disregard  it  for  the  purpose 
of  the  opinion.  or  to  postpone  the  opinion  to  allow  time 
for  the  consideration  of  the  new  information. 
- 36  -ANNEX  5 
MAXIMUM  RESIDUE  LIMITS  RECOMMENDED  BY 
THE  COMMITTEE  FOR  VETERINARY  MEDICINAL  PRODUCTS 
FOR  RESIDUES  OF  CERTAIN  ACTIVE  SUBSTANCES 
USED  IN  VETERINARY  MEDICINE 
This  Annex  contains  21  recommendations  for  MRLs  for  certain 
active  substances  used  in  veterinary  medicines. 
Copies  of  summaries  of  the  evaluation  of  these  compounds  by 
the  Committee  for  Veterinary  Medicinal  Products  are  available 
upon  request,  in  English  or  in  French,  from  the  Secretariat  of 
the  Committee  within  the  Commission  of  the  European  Communities 
at  the  address  given  in  Annex  2. 
Comments  on  these  recommendations  are  invited  from  interested 
parties,  and  should  reach  the  Commission  before  1  September 
1991. 
- 37  -TABLE  OF  MAXIMUM  RESIDUE  LIMITS  RECOMMENDED  BY  THE  COMMITTEE  FOR  VETERINARY 
MEDICINAL  PRODUCTS  FOR  RESIDUES  OF  CERTAIN  ACTIVE  SUBSTANCES 
USED  IN  VETERINARY  MEDICINE 
Notes  for  reading  the  table 
1.  ADI  stands  for  Acceptable  Dally  Intake.  It  Is  presented  In  a  range  from 
0  up  to  the  maximum  acceptable dally  Intake  expressed  In  terms  of 
micrograms  per  kilogram of  bodywelght  per  day.  The  entry  N/A  under  the 
ADI  column  means  that  no  ADI  has  been  allocated  for  the  compound 
concerned. 
2.  MRL  stands  for  Maximum  Residue  Limit.  The  MRL  Is  expressed  in  terms  of  a 
marker  residue,  which  may  be  the  parent  drug,  a  metabol lte, or  a 
combination  thereof.  Unless otherwise stated,  the  marker  residue  is  the 
same  for  alI  target  food  commodities.  For  example,  In  the  case of 
febantel  (No  8),  the  marker  residue  Is  the  sum  of oxfendazole, 
oxfendazole  sulfone  and  fenbendazole  found  In  the  target  food  commodity. 
3.  The  target  food  commodity  represents  the  food  commodities  in  which  the 
residue  may  be  expected  to  be  present. 
The  reference  "meat,  alI  tissues"  means  muscle,  kidney,  I lver  and  fat. 
Unless  otherwise  stated,  MRLs  for  meat  tissues  cover  alI  species 
including  bovine,  ovine,  porcine,  equine,  poultry  and  aquatic  species. 
Where  compounds  are  authorized  for  use  In  laying  birds or  lactating 
animals,  eggs  or  milk,  as  appropriate,  are  always  Included  among  the 
target  food  commodities.  If  eggs  or  milk  are  not  Included  it  means  that 
the  compound  concerned  Is  not  authorized  for  use  In  laying  birds or 
lactating  animals,  and  no  residues  should  be  present  In  these  food 
commodities. 
4.  The  last  column  indicated  the  status of  the  MRL. 
If  the  term  "final"  Is  used,  this means  that  the  CVMP  considers  that 
sufficient  data  Is  aval fable  to enable  a  definitive  MRL  to  be  adopted, 
and  to  enable  the  compounds  concerned  to  be  Included  In  Annex  1 of 
Councl 1 Regulation  2377/90. 
"Prov"  means  provisional.  If  this  term  is used,  It  means  that  the 
Committee  considers  that  the  data  avai fable  is  not  sufficient  to 
determine  a  definitive MRL.  However,  sufficient  data  Is  avai fable  to 
permit  the  establ lshment  of  a  provisional  MRL,  and  to enable  the  compound 
to  be  included  In  Annex  I I I  of  Councl I  Regulation  2377/90.  The  date 
following  the  reference  to  provisional  is  the  time  limit  recommended  by 
the  Committee  for  the  submission of  the  additional  data  necessary  to 
enable  a  final  MRL  to  be  establ lshed. 










TA.ULE  OF  l\1-\,"'lMJvl  RESIIXJE  LLvHTS  RECOvMENDED  BY  'lHE  COvtvUTl'EE  FOR  VErERINARY  MEDICINAL  PRaxx:TS 
FOR  RES IIXiES  OF  CERTAIN  ACfiVE  SUI3STAJ\'CES  USO:J  IN  VETERINARY  MEDICINE 
CX11KX1\D  mL  MRL( s)  M\RKEJs  RESII!JE  TARGET  fiX)) CDvMDIJY 
Chloramphenicol  NIA  10  ,ug/kg  Parent  drug  Meat,  all  tissues* 
Su l fonamides  ':-J.IA  100  ,ug/kg  Parent  drug  Meat,  all  tissues, 
group  100  ,ug/kg  Milk 
Tr ime thop rim  N/A  so  ,ug/kg  Parent  drug  Meat,  all  tissues, nillk 
Nitrofurans  group  N/A  5  ,ug/kg  All  residues with  Meat,  all  tissues,  eggs 
intact  5-nitro 
structure 
Dapsone  0-3.5 ,ug/kg  bw/d  25  ,ug/kg  Parent  drug  Meat,  all  tissues, nlilk 
Dimetridazole  NIA  10  ,ug/kg  All  residues with  Meat,  all  tissues 
intact  nitro-imidazole 
structure 
Ronidazole  N/A  2  ,ug/kg  All  residues with  NWat,  all  tissues 
intact  nitro-
im.idazol e  s true ture 
STATIJS 
Prov,  1.1.  94 
Final 
Prov,  1.1.  94 
Final 
Prov,  1. 1.  93 
Prov,  1.1.  94 
Prov,  1.1.94 
Prov,  1.1.94 
No  r-.1RLs  are  allocated  for  residues  of  chloramphenicol  in milk  or  egg:;  because  the  CvMP  specifically  reccmnends  that 
this  canpound  not  he  authorised  for  use  in  lactating  animals  or  laying  birds. I 
~ 
0 
CTh1J.UlJ'\D  .ADl..  MRL( s)  1\~SIOOE  TARGEf  F<XD___fll..MDI1Y  STAniS 
8.  Febantel*  N/A  1000  fl.g/kg  oxfendazole  +  Liver  Prov,  1 .1.  92 
10  /Lg/kg  oxfendazole  - MUscle,  kidney,  fat  Prov,  1.1.92 
10  fl.g/kg  sulphone  +  M.i lk  Prov,  1.1.92 
fenbendazole 
9.  Fenbendazole*  N/A  1000  /Lg/kg  oxfcndazole  +  Liver  Prov,  1 .1 . 92 
10  /Lg/kg  oxfendazole  - MUscle,  kidney,  fat  Prov,  1 . 1 . 92 
10  /Lg/kg  sulphone  +  Milk  Prov,  1.1.92 
fenbendazole 
10.  Oxfendazole  0-2 .s  fl.g/kg  bw/d  1000  /Lg/kg  oxfendazole  +  Liver  Prov,  1 .1 . 92 
10  /Lg/kg  oxfendazole  - MUscle,  kidney,  fat  Prov,  1.1.92 
10  fl.g/kg  sulphone  Milk  Prov,  1.1.  92 
11 .  Ivermectin  0-0.2 /Lg/kg  bw/d  15  fl.g/kg  H2B1a  metabolite  Liver  Final 
20  fl.g/kg  Fat  Final 
12.  Levami sol  N/A  10 fl.g/kg  Parent  drug  Meat,  all  tissues, milk  Prov,  1 . 1 . 95 
13.  Carazolol  0-0.2 fl.g/kg  b\v/d  50  /Lg/kg  Parent  drug  Liver,  kidney  Prov,  1.1.92 
5  /Lg/kg  Muscle,  fat  Prov,  1.1.92 
14.  Azaperone  0-0.8  /Lg/kg  b\v/d  100 fl.g/kg  Azaperol  Kidney  Prov,  1.1.92 
50  fl.g/kg  Azaperol  Liver,  muscle,  fat  Prov,  1.1.  92 
Tbe  Corrntittee  ~as agreed  that  there  is  no  need  to  establish  separate ADis  for  febantel  and  fenbendazole  because  these 
are metabolised  into  oxfendazole,  ~ich is  the rnore  toxic metabolite. ffiiPCX.J?\1)  .AI2l  Mli.ls)  M-\I~KFR RESliXJE  'fARGEl'  FaD CThMDI1Y  STA1US 
15.  Benzylpenicillin  NIA  50  p.g/kg  Parent  drug  Meat,  all  tissues  Final 
4  p.g/kg  Milk  Final 
16 .  .Ampicillin  NIA  50  p.g/kg  Parent  drug  Meat,  all  tissues  Final 
4  p.g/kg  Milk  Final 
1  7 .  knox i c i 11 in  NIA  50  p.g/kg  Parent  drug  Meat,  all  tissues  Final  4  p.g/kg  Milk  Final 
18.  Oxacillin  NIA  300  p.g/kg  Parent  drug  Meat,  all  tissues  Final 
30  p.g/kg  Milk  Final 
.r:-- 19.  Cloxacillin  NIA  300  p.g/kg  Parent  drug  Meat,  all  tissues  Final 
30  p.g/kg  Milk  Final 
20.  Dicloxacillin  N/A  300p.g/kg  Parent  drug  Meat,  all  tissues  Final 
30p.g/kg  Milk  Final 
21.  Tetracyclines  0-3  p.g/kg  bw/d  600  p.g/kg  Parent  drug  Kidney  Prov,  1.1.94  group  300  p.g/kg  Liver  Prov,  1 . 1 . 94  200  p.g/kg  Eggs  Prov,  1.1.94  100  p.g/kg  Muscle  Prov,  1.1.94  100  p.g/kg  Milk  Prov,  1. 1.  94  10  p.g/kg  Fat  Prov,  1.1.94 A N N E X  6 
COMMITTEE  FOR  VETERINARY  MEDICINAL  PRODUCTS 
General  considerations  for  the  establishment  of 
withdrawal  periods  for  veterinary medicinal  products 
The  protection of  consumers  of  foodstuffs  of  animal  origin  against  possible 
harmful  effects  resulting  from  the  Ingestion of  residues of  veterinary 
medicinal  products  depends  upon  three  factors: 
1.  the  safety assessment  of  residues of  pharmacologically  active  compounds 
used  in  veterinary medicine,  leading,  where  necessary,  to  the 
determination of  an  acceptable  dally  Intake  without  risk  for  the 
consumer,  and  maximum  residue  I imits  (MRLs)  for  edible  food  commodities; 
2.  the  determination of  the  withdrawal  period  necessary  to  ensure  that 
foodstuffs  taken  from  treated animals  do  not  contain  residues  in  excess 
of  the  MRLs; 
3.  the  routine  control  of  foodstuffs  of  animal  origin,  to  ensure  that  the 
MRL  is  not  in  practice exceeded. 
The  withdrawal  period  is  the  interval  necessary  between  the  last 
administration  to  animals  of  the  veterinary medicinal  product  under  normal 
conditions of  use  and  the  time  when  treated  animals  can  be  slaughtered  for  the 
production of  foodstuffs,  or  the  time  during  which  milk  and  eggs  must  be 
discarded  due  to  the  I lkely  presence  of  unsafe  residues of  the  medicinal 
product  in  these  foodstuffs. 
The  withdrawal  period  should  provide  a  high  degree  of  assurance  both  to 
producers  and  consumers  that  the  concentration of  residues  in  food  derived 
from  treated  animals  Is  not  above  the  permitted  concentrations. 
If  the  withdrawal  period  is  to  fulfil  Its  purpose  as  a  practical  instrument 
for  the  protection of  pub! ic  health,  it  is  Important  to  ensure  that  the 
withdrawal  period  can  in  practice be  observed.  This  impl les  that  the  length 
of  the  withdrawal  period must  be  compatible with  the  normal  conditions of  use 
of  the  veterinary medicinal  product. 
The  preamble  to Directive 81/852/EEC sets out  the  fundamental  principle  that  a 
decision  to authorize  a  veterinary medicinal  product  can  only  be  taken after 
an  evaluation of  the quality,  safety  and  efficacy of  the  medicinal  product 
concerned.  The  applicant  Is  required  to demonstrate  that  the  potential 
hazards  of  a  veterinary medicinal  product  are outweighed  by  the  therapeutic 
efficacy of  the  product.  Fai I lng  such  a  demonstration,  the  appl !cation must 
be  rejected. 
Both  the  duration of  the  withdrawal  period  and  the  practical  feasibility  of 
observance of  the  withdrawal  period  are  therefore aspects of  the  potential 
hazard  which  need  to  be  taken  Into consideration  when  deciding  whether  or  not 
authorization may  be  granted. 
- 42  -In  general  terms,  It  Is  I ikely  that  problems  of  observance  of  withdrawal 
periods  wi  I i  be  greatest  in  the  case  of  veterinary medicinal  products  Intended 
for  use  in  animals  producing  foodstuffs  on  a  dally  basis  such  as  eggs  or  milk. 
Particular  problems  arise  In  the  case of  products  Intended  for  the  mass 
medication of  laying  birds  In  large-scale  production  units~· where  any 
withdrawal  period  may  be  unacceptable. 
The  Committee  for  Veterinary Medicinal  Products  has  been  Informed  that  In  the 
case of  older  veterinary medicinal  products,  which  have  been  on  the market  for 
many  years,  the  Information available  about  residue  kinetics  Is often 
insufficient.  As  a  result,  the  competent  national  authorities  take  a 
conservative  approach  to  the  determination of  withdrawal  periods  and  sometimes 
use  an  additional  safety  span  when  determining  withdrawal  periods  for  these 
products.  The  problem  which  then  arises  Is  whether  such  lengthy  withdrawal 
periods  are  compatible  with  the  normal  conditions of  use  of  these  products. 
In  order  to support  the  maintenance on  the  market  of  these  old products,  the 
Committee  would  encourage  manufacturers  to  conduct  residue  depletion  studies, 
so  that  the  information  necessary  for  the  establ lshment  of  adequate  but 
real lstic withdrawal  periods  may  be  provided. 
- 43  -